Emollient for maintenance therapy after topical corticotherapy in mild psoriasis

Experimental Dermatology

Volumn 18, Issue 12, 2009, Pages 1076-1078

  Seite S ^a   Khemis, A ^b   Rougier, A ^a   Ortonne, J P ^b  

^a La Roche Posay Pharmaceutical Laboratories   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Clinical trial; Corticotherapy; Emollient; Psoriasis

Indexed keywords

CORTICOSTEROID; EMOLLIENT AGENT;

CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRY SKIN; HUMAN; LETTER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MOISTURE; PSORIASIS; QUALITY OF LIFE;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; DRUG THERAPY, COMBINATION; EMOLLIENTS; HUMANS; PSORIASIS; QUALITY OF LIFE; RECURRENCE; SEVERITY OF ILLNESS INDEX; SKIN; TREATMENT OUTCOME;

EID: 70849121902     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.00903.x     Document Type: Letter

References (15)

1. Christophers E, Mrowietz U, Freedberg I M, Eisen A Z, Wolff K. Psoriasis. Fitzpatrick's Dermatology in General Medicine 2003, 407-427. In, eds, McGraw-Hill Companies Inc, New York, USA
2. Dubertret L, Mrowietz U, Ranki A. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006, 155:729-736.
3. Lecluse L L A, Naldi L, Stern R S, Spuls P I. National registries of systemic treatment for psoriasis and the European " Psonet" Initiative. Dermatol. 2009, 218:347-356.
4. Heydendael V M, de Borgie C A, Spuls P I, Bossuyt P M, Bos J D, de Rie M A. The burden of psoriasis is not determined by disease severity only. J Invest Dermatol Symp Proc 2004, 9:131-135.
5. Van de Kerkhof P C, Barker J, Griffiths C E M. Psoriasis: consensus on topical therapies. J Eur Acad Dermatol Venereol 2008, 22:859-870.
6. Fluhr J W, Cavallotti C, Berardesca E. Emollients, moisturizers and keratolytics agents in psoriasis. Clin Dermatol 2008, 26:380-386.
7. Proksch E. The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol 2008, 21:75-80.
8. Hagemann I, Proksch E. Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Derm Venereol 1996, 76:353-356.
9. Caussin J, Groenink H W, de Graaf A M. Lipophilic and hydrophilic moisturizers show different actions on human skin as revealed by cryo scanning electron microscopy. Exp Dermatol 2007, 16:891-898.
10. Kraft J N, Lynde C W. Moisturizers: what they are and a practical approach to product selection. Skin Therapy Lett 2005, 10:1-8.
11. Lodén M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol 2003, 4:771-788.
12. Berth-Jones J, Grotzinger K, Rainville C. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. Br J Dermatol 2006, 155:707-713.
13. Finlay A Y, Khan G K. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19:210-216.
14. Roberts M S, Cross S E, Anissimov Y G. Factors affecting the formation of a skin reservoir for topically applied solutes. Skin Pharmacol Physiol 2004, 17:3-16.
15. Carey W, Glazer S, Gottlieb A B. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006, 54:S171-S181.